Edwards Lifesciences EW · NYSE
$87.21 +0.70% (+$0.61)
Summary
61 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 15 USD is left as net profit.
- It holds more cash than debt: $2.91B against $704.4M.
- Analysts expect revenue to grow by 12% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share fell by 9.1% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 50.0 USD for 1 USD of yearly profit. Over the last five years it was 35.1 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.7% a year over 5 years. Over the last 3 years it grew by 4.1% a year. For the next fiscal year analysts expect revenue to grow by 12%. Earnings per share fell by 9.1% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 22 USD
- Research and development 17 USD
- Sales and administration 33 USD
- Taxes and other 13 USD
- Net profit 15 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 15 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 33
- Hold 16
- Sell 0
Today's price within the analysts' price targets
The average target of $101.7 is 17% above today's price. 67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Transcatheter Heart Valves 74%
- Surgical Heart Valve Therapy 17%
- Transcatheter Mitral And Tricuspid Therapies 9.1%
By region
- UNITED STATES 58%
- Europe 25%
- Rest of World 11%
- JAPAN 5.8%
Transcatheter Heart Valves brings in 74% of revenue. Transcatheter Mitral And Tricuspid Therapies grew fastest, by 59% a year.
Segments in detail